assignment
Recruiting

Evaluation of Prednisolone Dosing Frequency on Glycemic Control in ANCA-Associated Vasculitis Patients Using Continuous Glucose Monitoring

Trial ID
2024-516141-39-00

Register record, history and transparency: CTIS.eu

Trial statistics

science
1
test molecule
location_city
1
research site
public
1
country
medical_information
1
disease
person_search
1
investigator

Diseases & Conditions

Anti-neutrophil cytoplasmic antibody positive vasculitis

Objectives

The primary objective of this study is to evaluate whether splitting the **cortisone** dose to a twice daily administration leads to increased time in the glucose target range in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides and rapid-progressive glomerulonephritides (RPGN). This is clinically relevant as maintaining blood glucose levels within the target range is crucial for minimizing complications associated with hyperglycemia, particularly in patients receiving corticosteroid therapy.

Secondary objectives include the evaluation of whether splitting the cortisone dose to a twice daily dose results in an improvement in 24-hour blood sugar levels, specifically addressing hyperglycemia and insulin management. This assessment is important for optimizing treatment regimens and improving patient outcomes in the management of blood glucose levels.

Participants

The sponsor did not provide information regarding the total number of participants in this clinical trial. The study population comprises both **male and female** patients, aged between 18 and 80 years, who have been newly diagnosed with **ANCA-associated vasculitis** or are experiencing a relapse of a known condition. Participants are required to have an Aprednislon dose of 1 mg/kg body weight at the time of inclusion. The trial does not involve a vulnerable population. Participants are expected to wear a continuous glucose monitoring (CGM) system for the study's duration and receive insulin therapy as needed. The selection criteria include a written agreement to participate following a detailed explanation of the study. Lifestyle considerations such as diet and physical activity are not specified in the provided data.

Plans and Procedures

The clinical trial is designed to evaluate the effect of once versus twice daily administration of **corticosteroids** on blood glucose levels in patients with **ANCA-associated vasculitis**. This study is a randomized, double-blind, controlled trial, aiming to determine if splitting the cortisone dose to a twice daily regimen leads to increased time in the glucose target range. The trial is expected to run from September 15, 2019, to December 31, 2024, with a maximum treatment period of 14 days for each participant. Participants will be administered **prednisolone** in tablet form, with a maximum daily dose of 1 mg/kg body weight and a total dose not exceeding 14 mg over the treatment period.

The sequence of study visits includes an initial screening visit to confirm eligibility based on criteria such as age (18-80 years), new diagnosis or relapse of **ANCA-associated vasculitis**, and willingness to use a continuous glucose monitoring (CGM) system. Following the screening, participants will be randomized into one of the treatment arms. Follow-up visits will be conducted to monitor blood glucose levels using blinded CGM, assess insulin therapy needs, and evaluate any adverse events. The primary endpoint is the mean time in the target glucose range (70-180 mg/dl), while secondary endpoints include various glucose metrics, insulin usage, and quality of life assessments. The end-of-study visit will involve a comprehensive evaluation of the participant's health status and study outcomes.

Participant involvement is expected to last for the duration of the treatment period, with conditions for early termination including withdrawal of consent, significant protocol deviations, or adverse events that compromise participant safety. The trial is conducted under strict adherence to ethical guidelines and regulatory requirements, ensuring the integrity and reliability of the data collected.

Treatment

The clinical trial involves the administration of **Aprednislon 1 mg Tabletten**, which contains the active substance **prednisolone**. This medication is provided in the form of a **tablet** and is intended for **oral** administration. The maximum daily dose is 1 mg, with a total maximum dose of 14 mg over a treatment period of 14 days. The trial aims to evaluate the effects of once versus twice daily administration of corticosteroids on blood glucose levels in patients with ANCA-vasculitis, as measured by continuous blood glucose monitoring. The study investigates whether splitting the cortisone dose into a twice-daily regimen leads to increased time within the glucose target range.

There are no non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, specified in this study. The trial focuses solely on the administration of the experimental medication, Aprednislon 1 mg Tabletten. Participant compliance with the dosing schedule will be monitored throughout the study to ensure adherence to the prescribed regimen. The pharmaceutical product is manufactured by Merck Gesellschaft MBH and is not a pediatric formulation. The active substance, prednisolone, is of chemical origin, and the product is authorized for use in Austria.

Efficacy

Efficacy in this clinical trial will be assessed by evaluating the impact of once versus twice daily administration of corticosteroids on blood glucose levels in patients with ANCA-associated vasculitis. The primary endpoint for efficacy is the mean time in the target glucose range of 70-180 mg/dL, as measured by blinded continuous glucose monitoring (CGM). Secondary endpoints include the number and percentage of glucose values within specified ranges, average daily blood glucose levels, mean blood glucose at specific times, and the number of insulin injections per day. Additional secondary endpoints involve assessments of relevant concomitant and diabetes medications, HbA1c levels, and various biomarkers such as **C-reactive protein (CRP)**, leukocytes, thrombocytes, and creatinine at initial diagnosis and during the course of the disease. Quality of life will be measured using the SF-36 and KDQOL questionnaires.

Data collection will involve the use of CGM systems to continuously monitor blood glucose levels, with specific timepoints for data analysis including preprandial and bedtime glucose values. The trial will also consider the Birmingham Vasculitis Score (BVAS) on discharge and antibody titers at initial diagnosis and during the disease course. The study is designed to determine whether splitting the cortisone dose to a twice daily regimen leads to increased time within the glucose target range, thereby assessing the efficacy of the treatment regimen in managing blood glucose levels in the specified patient population.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Written agreement to participate in the study after detailed explanation of the study
  • Male or female patients
  • New diagnosis of ANCA-associated vasculitis or a relapse of a known ANCA vasculitis
  • Age: ≥18-80 years at the time of biopsy
  • Aprednislon dose of 1mg/kg body weight at the time of inclusion
  • Wants to wear a CGM system for the duration of the study and to receive insulin therapy as needed
cancel

Exclusion Criteria

  • Known diabetes mellitus
  • Women capable of giving birth who are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception.
  • Skin changes or concomitant circumstances that prevent the placement of a glucose sensor in the examiner's assessment (e.g. scar tissue)
  • Current participation in another clinical trial that would affect study results
  • Relevant acute or chronic disease that, in the investigator's estimation, could affect the patient's safety or affect the study results.
  • Patient's inability to follow study procedures as required
  • Inability of the patient to understand the consent form

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Austria AustriaRecruiting15 Sept 201910

Sites & Investigators

Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
Aprednislon 1 mg Tabletten
TestTABLETTENORAL114PRD10567874

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Prednisolone
128 trials

Also investigated for

Diffuse large B-cell lymphoma 10Hormone-refractory prostate cancer 9Follicular lymphoma 6Acute lymphocytic leukaemia 5